Menu

PNAS Editor-in-Chief Placed on Leave

In a gender discrmination lawsuit against the Salk Institute, a female scientist alleges that biologist Inder Verma was dismissive of his female colleagues. 

Jan 5, 2018
Katarina Zimmer

FLICKR, SHINYA SUZUKI Inder Verma, a renowned cancer biologist at the Salk Institute for Biological Studies, has been placed on leave as editor-in-chief of the Proceedings of the National Academy of Sciences (PNAS) as of Monday this week (January 1).

The move is linked to three gender discrimination lawsuits that were filed by Salk professors Vicky Lundblad, Katherine Jones, and Beverly Emerson in July 2017, Verma tells The San Diego Union-Tribune. Emerson told Science last July that the world-leading institute was a “hostile environment in which [the women were] undermined, disrespected, disparaged, and treated unequally.” 

In one of the lawsuits, Lundblad alleges that Verma was one of the leaders at Salk who had been dismissive of female scientists, Science reports.  

Nobel laureate Elizabeth Blackburn, a molecular biologist who has been the president of Salk since 2015, has said that the allegations are false, according to The San Diego Union-Tribune. However, the lawsuit filed by Emerson alleges that Blackburn was one of Salk’s leaders who had been aware of the gender discrimination, Science reports.

Blackburn announced last month (December 21) that she will step down from her position at the end of the summer.

Verma, who joined Salk in the 1970s and has extensive experience in basic genetic research and cancer, was appointed editor-in-chief of PNAS in 2011. 

“As you can imagine, the Council’s decision saddens me deeply, particularly because the lawsuits have nothing to do with my work with NAS and I am not named individually for any claim,” Verma wrote in a December email to the editorial board of PNAS, according to The San Diego Union-Tribune.

“That said, I recognize the sensitivities present in this current environment and have far too much esteem for NAS to risk the possibility that events related to Salk would in any way distract from the Academy’s extraordinary work, so I will gracefully step aside,” the email continues. “I very much look forward to working with you all again, hopefully soon.” 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.